Mobia Medical, Inc. (MOBI)
Compare with another name Open in your desk ↗
Mobia Medical, Inc. (MOBI) reported revenue of $14 million for Q2 FY2026, the quarter ended 30 June 2026, up 102.4% on the same quarter a year earlier. Net income was -$21 million, and diluted earnings per share $-1.10. The figures are the company's own, from the 10-Q it filed with the SEC on 11 August 2026.
Revenue$14 millionup 102.4%
Net income-$21 million
Diluted EPS$-1.10
QuarterQ2 FY2026ended 30 June 2026
Mobia Medical (MOBI) in brief
Mobia Medical had 33 million shares outstanding at the latest filed count.
Read more
At 30 June 2026 it carried $7 million of debt and $177 million of cash. At the close of 30 October 2026 the market cap of Mobia Medical was $351 million.Ratios
From the filings
ROEn/a
ROCEn/a
Operating marginn/a
Net marginn/a
FCF marginn/a
Interest covern/a
Debt to equity0.04
Cash conversionn/a
Share count, last 12 months-0.0%
Sales CAGR, 3 yearsn/a
Profit CAGR, 3 yearsn/a
EPS, TTMn/a
At the close of 30 October 2026
Price$10.54
Market cap$351 million
Stock P/En/a
Price to book2.03
EV / EBITDAn/a
Dividend yieldn/a
Market cap / salesn/a
52-week high$14.63
52-week low$8.08
Price, 1 yearn/a
Price CAGR, 3 yearsn/a
Price CAGR, 5 yearsn/a
Worked from the filed figures; hover a name for the formula.
Read more
The priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowings Mobia Medical, Inc. reports under its own heading, which is the only one it files; lease liabilities are separate lines. Nothing here is a valuation or a view.MOBIgreeksoup.ai
Daily prices to 30 October 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read more
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.The public record on MOBI
| Filings | 9 in twelve months: 6 current reports (8-K), about 4 officer or director change; 1 results of operations; 1 charter or bylaw amendment, or fiscal year change |
| Planned insider sales | no Form 144 notice in twelve months |
| Options tape | no listed options |
| 13F holders | 44 funds reported a position for the quarter to 30 June 2026; largest SR One Capital Management, LP |
| Insider trading | 1 sale and 18 purchases on Form 4 in twelve months |
| Congress | 0 House trades disclosed in six months |
| Short interest | 850,177 shares short, 6.46 days to cover at 15 October 2026 |
| Documents | the 10-K, the 10-Qs, the proxy and 1 earnings press release, each linked |
Quarterly results, the last 4 quarters
| Q1 FY2025 | Q2 FY2025 | Q1 FY2026 | Q2 FY2026 | |
|---|---|---|---|---|
| Revenue | 5.7 | 6.7 | 12.1 | 13.5 |
| Cost of revenue | 1.0 | 1.2 | 2.1 | 2.3 |
| Gross profit | 4.6 | 5.5 | 9.9 | 11.2 |
| Gross margin | 82% | 82% | 82% | 83% |
| R&D | 1.4 | 1.4 | 1.7 | 2.3 |
| SG&A | 13.6 | 14.5 | 25.2 | 26.9 |
| Operating income | -10.3 | -10.5 | -16.9 | -17.9 |
| Operating margin | -182% | -157% | -140% | -133% |
| Interest expense | 0.2 | 0.2 | 0.4 | 0.3 |
| Pre-tax income | -10.7 | -10.5 | -17.7 | -21.0 |
| Net income | -10.7 | -10.5 | -17.7 | -21.0 |
| Net margin | -188% | -157% | -147% | -156% |
| Diluted EPS | -$0.62 | -$12.44 | -$0.92 | -$1.10 |
| Operating cash flow | -9.7 | -11.0 | -17.7 | -15.7 |
| Capital expenditure | 0.0 | 0.0 | 0.0 | 1.5 |
| Free cash flow | -9.7 | -11.0 | -17.8 | -17.2 |
| Shares outstanding | 698m | 33m | 21m | 33m |
| Filing | 10-Q | 10-Q | 10-Q | 10-Q |
Each quarter as filed, linked to its filing.
Read more
Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.Questions
What is Mobia Medical's market cap?
The market cap of Mobia Medical was $351 million at the close of 30 October 2026.
How much debt does Mobia Medical have?
At 30 June 2026 Mobia Medical carried $7 million of debt and $177 million of cash.
Peers: Medical Equipment
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Stryker Corp. SYK | $110.9 billion | 31.03 | 15.4% | 20.7% | 7.9% | 0.64 | 1.2% |
| 3M Co. MMM | $90.1 billion | 25.98 | 85.7% | 18.8% | 1.7% | 3.63 | 1.8% |
| Boston Scientific Corp. BSX | $60.8 billion | 16.99 | 14.7% | 19.8% | 13.5% | 0.51 | n/a |
| Becton Dickinson & Co. BDX | $53.9 billion | 59.58 | 3.9% | 9.6% | -2.6% | 0.69 | 2.1% |
| Medline Inc. MDLN | $42.2 billion | n/a | n/a | n/a | n/a | 1.09 | n/a |
| Resmed Inc. RMD | $32.3 billion | 20.93 | 26.8% | 33.0% | 9.0% | 0.07 | 1.1% |
| Dexcom Inc. DXCM | $30.7 billion | 32.27 | 39.1% | 24.0% | 13.0% | 0.49 | n/a |
| West Pharmaceutical Services Inc. WST | $28.8 billion | 46.30 | 21.5% | 23.0% | 12.6% | 0.07 | 0.2% |
| Glaukos Corp. GKOS | $14.1 billion | n/a | -23.7% | -25.5% | 46.9% | 0.00 | n/a |
| Solventum Corp. SOLV | $13.8 billion | 9.94 | 29.9% | 25.0% | -0.9% | 1.06 | n/a |
| Penumbra Inc. PEN | $12.6 billion | 80.45 | 9.9% | 12.1% | 17.0% | 0.00 | n/a |
| Baxter International Inc. BAX | $11.9 billion | n/a | -11.1% | -1.9% | 5.3% | 1.32 | 2.3% |
All 110 in Medical Equipment
| Company | Market cap | P/E | ROE | Op. margin | Sales growth TTM | Debt to equity | Div. yield |
|---|---|---|---|---|---|---|---|
| Intuitive Surgical Inc. ISRG | $149.8 billion | 52.25 | 18.5% | 28.4% | 20.5% | 0.00 | n/a |
| Medtronic plc MDT | $123.6 billion | 23.78 | 10.4% | 18.1% | 9.8% | 0.56 | 3.0% |
| Stryker Corp. SYK | $110.9 billion | 31.03 | 15.4% | 20.7% | 7.9% | 0.64 | 1.2% |
| 3M Co. MMM | $90.1 billion | 25.98 | 85.7% | 18.8% | 1.7% | 3.63 | 1.8% |
| Boston Scientific Corp. BSX | $60.8 billion | 16.99 | 14.7% | 19.8% | 13.5% | 0.51 | n/a |
| Becton Dickinson & Co. BDX | $53.9 billion | 59.58 | 3.9% | 9.6% | -2.6% | 0.69 | 2.1% |
| Edwards Lifesciences Corp. EW | $53.1 billion | 52.88 | 9.5% | 22.3% | 14.6% | 0.06 | n/a |
| Medline Inc. MDLN | $42.2 billion | n/a | n/a | n/a | n/a | 1.09 | n/a |
| GE HealthCare Technologies Inc. GEHC | $34.6 billion | 16.16 | 18.5% | 13.3% | 6.9% | 0.86 | 0.2% |
| Resmed Inc. RMD | $32.3 billion | 20.93 | 26.8% | 33.0% | 9.0% | 0.07 | 1.1% |
| Dexcom Inc. DXCM | $30.7 billion | 32.27 | 39.1% | 24.0% | 13.0% | 0.49 | n/a |
| West Pharmaceutical Services Inc. WST | $28.8 billion | 46.30 | 21.5% | 23.0% | 12.6% | 0.07 | 0.2% |
| Koninklijke Philips N.V. PHG * | $25.9 billion | 25.86 | 8.2% | 8.0% | -1.0% | 0.74 | 1.4% |
| Steris plc STE | $22.1 billion | 27.77 | 11.2% | 18.9% | 8.4% | 0.26 | 1.1% |
| Zimmer Biomet Holdings, Inc. ZBH | $18.0 billion | 22.99 | 6.4% | 14.2% | 8.6% | 0.59 | 1.0% |
| Glaukos Corp. GKOS | $14.1 billion | n/a | -23.7% | -25.5% | 46.9% | 0.00 | n/a |
| Solventum Corp. SOLV | $13.8 billion | 9.94 | 29.9% | 25.0% | -0.9% | 1.06 | n/a |
| Smith & Nephew plc SNN * | $13.0 billion | 20.75 | 11.8% | 12.9% | 6.1% | 0.59 | 2.5% |
| Penumbra Inc. PEN | $12.6 billion | 80.45 | 9.9% | 12.1% | 17.0% | 0.00 | n/a |
| Baxter International Inc. BAX | $11.9 billion | n/a | -11.1% | -1.9% | 5.3% | 1.32 | 2.3% |
| Cooper Companies, Inc. COO | $11.3 billion | 20.32 | 6.8% | 12.8% | 4.7% | 0.31 | n/a |
| Align Technology Inc. ALGN | $10.7 billion | 26.08 | 9.8% | 13.2% | 4.4% | 0.00 | n/a |
| Globus Medical Inc. GMED | $10.5 billion | 19.96 | 11.2% | 20.3% | 19.7% | 0.00 | n/a |
| Insulet Corp. PODD | $10.4 billion | 28.00 | 26.4% | 16.9% | 29.4% | 0.67 | n/a |
| Bausch & Lomb Corp. BLCO | $7.1 billion | n/a | -1.7% | 7.1% | 8.9% | 0.79 | n/a |
| MSA Safety Inc. MSA | $6.9 billion | 22.21 | 22.4% | 21.2% | 6.5% | 0.43 | 1.2% |
| Teleflex Inc. TFX | $5.9 billion | n/a | -35.5% | 2.0% | 30.7% | 0.97 | 1.0% |
| Haemonetics Corp. HAE | $5.4 billion | 58.69 | 11.5% | 11.9% | 0.4% | 1.42 | n/a |
| Merit Medical Systems Inc. MMSI | $5.2 billion | 32.36 | 9.2% | 13.5% | 9.1% | 0.42 | n/a |
| MiniMed Group, Inc. MMED | $5.1 billion | n/a | n/a | n/a | n/a | 0.00 | n/a |
| Heartflow, Inc. HTFL | $5.1 billion | n/a | -42.3% | -37.8% | n/a | 0.00 | n/a |
| LivaNova plc LIVN | $4.3 billion | 23.36 | 14.2% | 12.7% | 12.4% | 0.22 | n/a |
| Integer Holdings Corp. ITGR | $4.3 billion | 42.49 | 6.0% | 8.2% | -0.3% | 0.71 | n/a |
| ICU Medical Inc. ICUI | $4.1 billion | 139.01 | 1.4% | 3.3% | -9.0% | 0.57 | n/a |
| iRhythm Holdings, Inc. IRTC | $4.1 billion | n/a | -7.5% | -3.0% | 25.6% | 3.50 | n/a |
| Envista Holdings Corp. NVST | $3.8 billion | 40.47 | 3.1% | 9.6% | 11.9% | 0.47 | n/a |
| Pulse Biosciences, Inc. PLSE | $3.7 billion | n/a | -80.5% | -7,007.8% | n/a | 0.00 | n/a |
| AtriCure, Inc. ATRC | $3.1 billion | 291.38 | 2.0% | 2.3% | 13.9% | 0.12 | n/a |
| Axogen, Inc. AXGN | $2.9 billion | n/a | -6.4% | -5.2% | 24.3% | 0.00 | n/a |
| Warby Parker Inc. WRBY | $2.7 billion | 351.50 | 2.0% | 0.2% | 11.0% | 0.00 | n/a |
| TransMedics Group, Inc. TMDX | $2.3 billion | 16.95 | 29.3% | 12.2% | 25.8% | 0.99 | 0.0% |
| UFP Technologies Inc. UFPT | $2.2 billion | 30.61 | 15.6% | 15.3% | 7.3% | 0.25 | n/a |
| Inspire Medical Systems, Inc. INSP | $2.0 billion | 14.73 | 16.4% | 6.0% | 4.3% | 0.00 | n/a |
| Dentsply Sirona Inc. XRAY | $1.9 billion | n/a | -40.4% | -8.5% | -0.8% | 1.65 | 6.7% |
| Establishment Labs Holdings Inc. ESTA | $1.9 billion | n/a | -180.0% | -7.6% | 38.6% | 12.11 | n/a |
| Lemaitre Vascular Inc. LMAT | $1.9 billion | 28.40 | 15.6% | 29.5% | 11.8% | 0.40 | 1.1% |
| Kestra Medical Technologies, Ltd. KMTS | $1.8 billion | n/a | -67.4% | -134.5% | 60.7% | 0.33 | n/a |
| Butterfly Network, Inc. BFLY | $1.7 billion | n/a | -29.1% | -46.9% | 39.3% | 0.00 | 0.0% |
| NovoCure Ltd. NVCR | $1.5 billion | n/a | -34.7% | -17.2% | 12.9% | 0.56 | n/a |
| Tandem Diabetes Care Inc. TNDM | $1.3 billion | n/a | -48.6% | -4.4% | 4.0% | 4.62 | n/a |
| Conmed Corp. CNMD | $1.3 billion | 18.30 | 6.9% | 9.9% | 1.6% | 0.77 | 1.4% |
| National Vision Holdings, Inc. EYE | $1.3 billion | 27.20 | 5.6% | 4.1% | 7.8% | 0.26 | n/a |
| Cadre Holdings, Inc. CDRE | $1.3 billion | 35.68 | 10.4% | 10.1% | 19.7% | 1.08 | 1.3% |
| SkinHealth Systems Inc. SKIN | $1.3 billion | n/a | -51.2% | -1.5% | -6.5% | 6.21 | n/a |
| Staar Surgical Co. STAA | $1.2 billion | 350.71 | 1.1% | 4.0% | 51.3% | 0.00 | n/a |
| Enovis Corp. ENOV | $1.1 billion | n/a | -74.6% | -45.1% | 4.9% | 0.87 | n/a |
| Bioventus Inc. BVS | $1.1 billion | n/a | n/a | n/a | 3.1% | 1.09 | n/a |
| Artivion, Inc. AORT | $1.1 billion | n/a | -0.7% | 4.4% | 16.4% | 0.82 | n/a |
| Procept BioRobotics Corp. PRCT | $1.1 billion | n/a | -32.3% | -33.9% | 22.7% | 0.15 | n/a |
| Alphatec Holdings, Inc. ATEC | $1.1 billion | n/a | n/a | -3.6% | 15.3% | n/a | n/a |
| Ceribell, Inc. CBLL | $1.0 billion | n/a | -51.4% | -68.6% | 31.7% | 0.16 | n/a |
| Integra LifeSciences Holdings Corp. IART | $992 million | 75.00 | 1.2% | 4.4% | 0.8% | 1.71 | n/a |
| Iradimed Corp. IRMD | $981 million | 41.03 | 22.5% | 32.3% | 11.0% | 0.00 | n/a |
| Si-Bone, Inc. SIBN | $950 million | n/a | -8.0% | -8.3% | 15.3% | 0.20 | 0.0% |
| Beta Bionics, Inc. BBNX | $909 million | n/a | -20.7% | -72.7% | 43.7% | 0.00 | n/a |
| Orthopediatrics Corp. KIDS | $806 million | n/a | -10.0% | -9.4% | 16.1% | 0.31 | n/a |
| Anteris Technologies Global Corp. AVR | $615 million | n/a | -41.2% | -4,738.4% | -9.6% | 0.00 | n/a |
| Mimedx Group, Inc. MDXG | $568 million | n/a | -9.1% | -8.3% | -22.8% | 0.00 | n/a |
| Tactile Systems Technology Inc. TCMD | $523 million | 21.35 | 11.1% | 10.0% | 17.2% | 0.00 | n/a |
| Sight Sciences, Inc. SGHT | $511 million | n/a | -56.3% | -33.4% | 9.3% | 0.77 | n/a |
| Angiodynamics Inc. ANGO | $509 million | n/a | -20.1% | -11.2% | 8.2% | 0.00 | n/a |
| Delcath Systems, Inc. DCTH | $486 million | 1,403.00 | 0.4% | -1.9% | 35.8% | 0.00 | n/a |
| Avita Medical, Inc. RCEL | $484 million | n/a | n/a | -46.6% | 1.0% | n/a | n/a |
| SS Innovations International, Inc. SSII | $469 million | n/a | -23.3% | -15.8% | 89.7% | 0.00 | n/a |
| Cerus Corp. CERS | $460 million | n/a | n/a | n/a | n/a | 0.93 | n/a |
| NeuroPace Inc. NPCE | $420 million | n/a | -160.9% | -15.3% | 11.6% | 4.97 | 0.0% |
| Carlsmed, Inc. CARL | $407 million | n/a | -43.1% | -61.1% | n/a | 0.18 | n/a |
| Shoulder Innovations, Inc. SI | $398 million | n/a | -28.2% | -58.5% | n/a | 0.12 | n/a |
| Orthofix Medical Inc. OFIX | $370 million | n/a | -14.4% | -4.7% | 3.0% | 0.52 | n/a |
| Orchestra BioMed Holdings, Inc. OBIO | $356 million | n/a | -305.5% | -181.4% | 986.1% | 1.80 | n/a |
| Embecta Corp. EMBC | $354 million | 4.22 | n/a | 21.9% | -7.6% | n/a | 7.4% |
| Mobia Medical, Inc. MOBI | $351 million | n/a | n/a | n/a | n/a | 0.04 | n/a |
| ClearPoint Neuro, Inc. CLPT | $342 million | n/a | -132.5% | -70.6% | 32.5% | 1.86 | n/a |
| CapsoVision, Inc. CV | $342 million | n/a | -226.6% | -217.1% | n/a | 0.00 | n/a |
| Sanara MedTech Inc. SMTI | $302 million | n/a | -403.0% | n/a | 12.9% | 5.85 | n/a |
| Cytosorbents Corp. CTSO | $290 million | n/a | n/a | -34.7% | 3.1% | n/a | n/a |
| Treace Medical Concepts, Inc. TMCI | $287 million | n/a | -87.9% | -26.2% | -4.0% | 0.83 | n/a |
| Anika Therapeutics, Inc. ANIK | $280 million | n/a | -2.8% | -4.2% | 5.3% | 0.00 | n/a |
| InfuSystem Holdings, Inc. INFU | $279 million | 34.17 | 14.4% | 9.3% | 2.5% | 0.35 | n/a |
| Orasure Technologies Inc. OSUR | $272 million | n/a | -15.5% | -48.1% | -18.9% | 0.00 | n/a |
| Profound Medical Corp. PROF | $239 million | 14.23 | -65.7% | -185.3% | 61.2% | 0.09 | n/a |
| TriSalus Life Sciences, Inc. TLSI | $227 million | n/a | -430.7% | -67.7% | 25.2% | 5.05 | n/a |
| Electromed, Inc. ELMD | $225 million | 20.53 | 20.9% | 18.8% | 15.3% | 0.00 | n/a |
| Utah Medical Products Inc. UTMD | $217 million | 20.83 | 8.6% | 28.4% | -7.0% | 0.00 | n/a |
| RxSight, Inc. RXST | $202 million | n/a | -17.8% | -45.5% | -17.7% | 0.00 | n/a |
| PRO DEX Inc. PDEX | $186 million | 15.95 | 24.4% | 16.8% | 13.3% | 0.33 | n/a |
| Inogen Inc. INGN | $184 million | n/a | -14.1% | -8.7% | 3.2% | 0.00 | n/a |
| Edap TMS SA FOCL | $158 million | n/a | n/a | n/a | n/a | n/a | n/a |
| Koru Medical Systems, Inc. KRMD | $138 million | n/a | -10.1% | -3.7% | 22.4% | 0.00 | n/a |
| Pulmonx Corp. LUNG | $129 million | n/a | -122.8% | -53.0% | -3.4% | 0.96 | n/a |
| Apyx Medical Corp. APYX | $108 million | n/a | -81.0% | -6.1% | 25.6% | 3.52 | n/a |
| Neuraxis, Inc. NRXS | $89 million | n/a | -114.0% | -144.5% | 65.2% | 0.01 | n/a |
| Lakeland Industries Inc. LAKE | $88 million | n/a | -21.4% | -4.1% | -0.4% | 0.23 | n/a |
| Stereotaxis, Inc. STXS | $86 million | n/a | -182.3% | -75.7% | -5.5% | 0.00 | n/a |
| Lucid Diagnostics Inc. LUCD | $77 million | n/a | -478.3% | -930.8% | 24.9% | 2.15 | n/a |
| Outset Medical, Inc. OM | $76 million | n/a | -77.1% | -56.1% | -1.3% | 1.01 | n/a |
| NutriBand Inc. NTRB | $76 million | n/a | -130.7% | -435.6% | -37.3% | 0.00 | n/a |
| Lensar, Inc. LNSR | $72 million | n/a | 232.8% | -13.5% | 3.3% | 0.25 | n/a |
| RenovoRx, Inc. RNXT | $60 million | n/a | -136.8% | -685.2% | n/a | 0.00 | n/a |
| PAVmed Inc. PAVM | $12 million | n/a | -34.5% | -23,841.1% | -89.0% | 0.43 | n/a |
70 companies share its SEC industry code (Surgical & Medical Instruments & Apparatus); the rest are the names nearest in size in its wider industry, Medical Equipment, one of the Fama-French 48 industries, a published grouping of SEC industry codes.